Clinical trials: Atezolizumab
Breast Cancer
Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast Cancer
This is a multi-centre, open label, phase 2, randomised controlled trial of patients with advanced triple negative breast cancer (TNBC) who have received no more than one line of chemotherapy (not including neoadjuvant or…
- Trial name
- AZTEC (NCT03464942)
- Testing
- SABR, Atezolizumab
- Where
- Australia
- Volunteers
- 54 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Non-small Cell Lung Cancer
A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC
This clinical research study is being carried out in two parts, Phase 1 and Phase 2. The primary purpose of the Phase 1 portion of the study is to observe the safety of the combination of rociletinib and MPDL3280A in EGFR-mutant…
- Trial name
- NCT02630186
- Testing
- Rociletinib, MPDL3280A
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Clovis Oncology, Inc.
Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer
Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation
This phase I/II trial studies the side effects, safety, and effectiveness of low dose radiation to the entire body (total body irradiation [TBI]) and higher dose radiation to known areas of cancer (hypofractionated radiation…
- Trial name
- TESSERACT (NCT06110572)
- Testing
- Carboplatin, Atezolizumab, Etoposide
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Solid Tumor
Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients
The purpose of this study is to determine whether cytoreduction of bulky metastatic disease using ultra high dose SBRT in combination with immunotherapy is tolerable and feasible In patients who have exhausted SoC treatment…
- Trial name
- NCT06416436
- Testing
- Atezolizumab, Stereotactic Ablative Radiotherapy (SBRT)
- Where
- United States
- Sponsor
- University of Kansas Medical Center
Hepatocellular Carcinoma
Regorafenib After Progression on Atezolizumab Plus Bevacizumab in Advanced HCC
To investigate efficacy and toxicity of regorafenib after treatment with atezolizumab and bevacizumab combination
- Trial name
- HCC (NCT05134532)
- Testing
- regorafenib
- Where
- 2 sites in South Korea
- Volunteers
- 40 people
- Sponsor
- CHA University
Non-small Cell Lung Cancer, Non-small Cell Carcinoma
Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC
The investigators hypothesize that the addition of ramucirumab and N-803 will augment the clinical activity of atezolizumab, and in order to evaluate the exact mechanism of action of the combination, the investigators propose a…
- Conditions
- Non-small Cell Lung Cancer, Non-small Cell Carcinoma, NSCLC, Non Small Cell Lung Cancer
- Trial name
- RAN (NCT05007769)
- Testing
- Ramucirumab, Atezolizumab, N-803
- Sponsor
- Washington University School of Medicine
Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7
Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study
This phase III trial studies how well combination chemotherapy, bevacizumab, and/or atezolizumab work in treating patients with deficient deoxyribonucleic acid (DNA) mismatch repair colorectal cancer that has spread from where it…
- Trial name
- NCT02997228
- Testing
- Atezolizumab, Bevacizumab, Biospecimen Collection
- Where
- 445 sites in United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Resectable Hepatocellular Carcinoma With High Risk of Recurrence
Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo
This is an open-label, single-arm, multicenter, prospective, phase II clinical study to evaluate the efficacy and safety of TACE combined with Atezolizumab and Bevacizumab as neoadjuvant treatment in Hepatocellular Carcinoma.
- Trial name
- ATTACH (NCT07239245)
- Testing
- Atezolizumab, Bevacizumab, Transarterial chemoembolization (TACE)
- Where
- 4 sites in China
- Volunteers
- 30 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Non-small Cell Lung Cancer
A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer
This is a Phase II, randomized, multi-center, multinational, open-label, cross-over study in adult participants with PD-L1-positive NSCLC.
- Trial name
- NCT05171777
- Testing
- Atezolizumab
- Where
- 36 sites in United States, Argentina and 10 more
- Volunteers
- 179 people
- Sponsor
- Hoffmann-La Roche
Non-small Cell Lung Cancer
Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity
DARWIN II is a multi-arm non-randomised phase II trial, Eligible patient will be those who relapse with NSCLC (clinical trials.gov ref. NCT02183883). .
- Trial name
- DARWINII (NCT02314481)
- Testing
- MPDL3280A, Vemurafenib, Alectinib
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- University College, London
Carcinoma, Thymic
A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma
This is a phase II, open-label, single-arm, multicenter study of the efficacy and safety of atezolizumab treatment in participants with advanced thymic carcinoma who failed prior systemic therapy.
- Trial name
- NCT04321330
- Testing
- Atezolizumab
- Where
- 10 sites in China
- Volunteers
- 34 people
- Sponsor
- Hoffmann-La Roche
Melanoma, Merkel Cell Carcinoma
High-Risk Skin Cancers With Atezolizumab Plus NT-I7
The purpose of this study is to test whether the addition of NT-I7 to atezolizumab provides clinically meaningful outcomes for patients with anti-PD-1/PD-L1 naive or relapsed/refractory high-risk melanoma, Merkel Cell Carcinoma…
- Conditions
- Melanoma, Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
- Trial name
- NCT03901573
- Testing
- NT-I7, atezolizumab
- Where
- 8 sites in United States
- Volunteers
- 31 people
- Sponsor
- NeoImmuneTech
Cancer
A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary
The goal of this clinical research study is to learn if the combination of atezolizumab and tiragolumab can help to control cancers of unknown primary. The safety and effects of this drug combination will also be studied
- Trial name
- NCT06754501
- Testing
- Atezolizumab, Tiragolumab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Treatment-Refractory Solid Tumors
A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients
This clinical trial aims to determine whether the administration of the investigational drug OTS-412, OTS-412 in combination with hydroxyurea or hydroxyurea/atezolizumab is safe and effective for patients with various types of…
- Trial name
- NCT07170592
- Testing
- OTS-412, Hydroxyurea (HU), Atezolizumab
- Volunteers
- 24 people
- Sponsor
- Bionoxx Inc.
Extensive Stage Lung Small Cell Carcinoma
Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer
This phase II trial studies the effect of lamivudine in combination with standard of care chemoimmunotherapy in treating patients with extensive stage small cell lung cancer.
- Trial name
- NCT04696575
- Testing
- Atezolizumab, Carboplatin, Etoposide
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Roswell Park Cancer Institute
Stomach Neoplasms, Gastric Adenocarcinoma
Maintenance Therapy in Metastatic Gastric Cancer: A Multicenter Retrospective Study in Colombia
Metastatic gastric cancer has a poor prognosis, and the cumulative toxicity of first-line platinum and fluoropyrimidine chemotherapy limits how long treatment can be continued.
- Conditions
- Stomach Neoplasms, Gastric Adenocarcinoma, Metastatic Gastric Cancer
- Trial name
- NCT07856212
- Testing
- Fluoropyrimidine Maintenance Therapy, Immune Checkpoint Inhibitor Maintenance, Targeted Therapy Maintenance
- Where
- 4 sites in Colombia
- Volunteers
- 150 people
- Sponsor
- Fundación Santa Fe de Bogota
Hepatocellular Carcinoma
Efficacy and Safety of TACE in Combination With ICIs for HCC: a Real-world Study
The purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) in patients with hepatocellular carcinoma (HCC) .
- Trial name
- CHANCE001 (NCT04975932)
- Testing
- TACE+ICIs, TACE
- Where
- China
- Volunteers
- 826 people
- Sponsor
- Zhongda Hospital
Metastatic Renal Cell Carcinoma (mRCC)
International Multicentric Study ARON-1
The ARON-1 Study is designed as an International Multicentric Retrospective Study to collect global experiences with the use of immuno-combinations in patients with metastatic RCC.
- Trial name
- NCT05287464
- Testing
- pembrolizumab plus axitinib
- Where
- Italy
- Volunteers
- 1,220 people
- Sponsor
- Hospital of Macerata
Solid Tumors, Mycosis Fungoides
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
This is a multicenter, open-label, phase 1 study conducted to test intratumoral injections of TTI-621 in subjects that have relapsed and refractory percutaneously accessible solid tumors or mycosis fungoides.
- Conditions
- Solid Tumors, Mycosis Fungoides, Melanoma, Merkel-cell Carcinoma
- Trial name
- NCT02890368
- Testing
- TTI-621 Monotherapy, TTI-621 + PD-1/PD-L1 Inhibitor, TTI-621 + pegylated interferon-α2a
- Where
- 7 sites in United States
- Volunteers
- 56 people
- Sponsor
- Pfizer
Carcinoma, Non-Small-Cell Lung
A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)
This study will evaluate the efficacy, safety, and pharmacokinetics of immunotherapy-based treatment combinations in participants with metastatic non-small cell lung cancer (NSCLC).
- Trial name
- Morpheus Lung (NCT03337698)
- Testing
- Atezolizumab, Cobimetinib, RO6958688
- Where
- 29 sites in United States, Australia and 5 more
- Volunteers
- 314 people
- Sponsor
- Hoffmann-La Roche